Risperidone
- Generic Name
- Risperidone
- Brand Names
- Perseris, Risperdal, Rykindo, Uzedy, Okedi
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27FN4O2
- CAS Number
- 106266-06-2
- Unique Ingredient Identifier
- L6UH7ZF8HC
- Background
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...
- Indication
Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...
- Associated Conditions
- Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
- Associated Therapies
- -
A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2011-01-24
- Target Recruit Count
- 158
- Registration Number
- NCT00253149
A Study of the Effectiveness and Safety of Long-acting Injectable Risperidone Versus Placebo in the Treatment of Patients With Schizophrenia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 458
- Registration Number
- NCT00253136
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 626
- Registration Number
- NCT00253123
A Comparison of Risperidone With Haloperidol in Patients With Schizophrenia and Schizoaffective Disorder
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2012-08-06
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 396
- Registration Number
- NCT00253110
A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2010-11-25
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 151
- Registration Number
- NCT00250367
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 1579
- Registration Number
- NCT00249119
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2011-01-14
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 349
- Registration Number
- NCT00249145
A Study of Risperidone in Combination With Lorazepam Compared With Standard Therapy for Emergency Treatment of Schizophrenic Patients
Phase 4
Completed
- Conditions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2011-01-14
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 226
- Registration Number
- NCT00249171
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 523
- Registration Number
- NCT00249132
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-11-07
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- Janssen-Cilag Pty Ltd
- Target Recruit Count
- 344
- Registration Number
- NCT00249158
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath